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a  b  s  t  r  a  c  t
Polycyclic  aromatic  hydrocarbons  (PAHs)  are ubiquitous  in the  human  environment.  Since  they  are
present  in  crude oilfractions  used  for the  production  of  rubber  and  plastics,  consumers  may  come into
direct dermal  contacts  with  these  compounds  (e.g.,  via  tool  handles)  on  a daily  basis.  Some  individual
PAHs  are  identified  as  genotoxic  mutagens  thereby  prompting  particular  toxicological  and  environmen-
tal  concern.  Among  this  group,  benzo[a]pyrene  (BAP)  constitutes  a  model  carcinogen  which  is also  used
as  reference  compound  for risk  assessment  purposes.  It  acts  as  a strong  agonist  of  the  aryl  hydrocarbon
receptor  (AHR)  and  becomes  metabolically  activated  toward  mutagenic  and  carcinogenic  intermediates
by  cytochrome  P450-dependent  monooxygenases  (CYPs).  While  BAP  has been  exhaustively  characterized
with  regard  to its toxicological  properties,  there  is much  less  information  available  for  other  PAHs.  We
treated  an  AHR-proficient  immortal  human  keratinocyte  cell  line  (i.e., HaCaT)  with  three  selected  PAHs:
BAP, chrysene  (CRY)  and  dibenzo[a,l]pyrene  (DALP).  Compound-mediated  alterations  of  endogenous
metabolites  were  investigated  by  an  LC–MS/MS-based  targeted  approach.  To  examine  AHR-dependent
changes  of the measured  metabolites,  AHR-deficient  HaCaT  knockdown  cells  (AHR-KD)  were  used  for
comparison.  Our  results  reveal  that 24  metabolites  are  sufficient  to  separate  the PAH-exposed  cells  from
untreated  controls  by  application  of  a multivariate  model.  Alterations  in  the  metabolomics  profiles  caused
by  each  PAH  show  influences  on  the  energy  and  lipid  metabolism  of the  cells  indicating  reduced  tricar-
boxylic  acid  (TCA)  cycle  activity  and  -oxidation.  Up-regulation  of sphingomyelin  levels  after  exposure
to  BAP  and  DALP  point  to pro-apoptotic  processes  caused  by these  two  potent  PAHs.  Our results  suggest
that  in  vitro  metabolomics  can  serve  as tool  to develop  bioassays  for application  in  hazard  assessment.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. IntroductionIn daily life, consumers are exposed to a variety of potentially
oxic compounds that may  be released from consumer products
Abbreviations: AAs, amino acids; ACs, acyl carnitines; AHR, aryl hydrocar-
on receptor; BAs, biogenic amines; BAP, benzo[a]pyrene; CRY, chrysene; DALP,
ibenzo[a,l]pyrene; LPCs, lysophosphatidylcholines; PAHs, polycyclic aromatic
ydrocarbons; PCs, phosphatidylcholines; SMs, sphingomyelines.
∗ Corresponding author.
E-mail address: sarah.potratz@bfr.bund.de (S. Potratz).
ttp://dx.doi.org/10.1016/j.toxrep.2016.09.003
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
[1,2]. For instance, polycyclic aromatic hydrocarbons (PAHs) are
ubiquitous in the human environment. Generated from incomplete
combustion of organic matter like coal, grilled meat or cigarettes
they are present in air, food and soil [3–5]. Furthermore, PAHs occur
in crude oil fractions and carbon black used for the production of
rubber, certain plastics and elastomers [6,7]. Dermal contact with
consumer products containing petroleum and subsequent dermal
uptake of diesel oil and other lubricants were identified in human
volunteer trial experiments [8]. Therefore, direct skin contact (e.g.,
via tool handles or lubricants and fuels) in combination with pos-
sible migration is supposed to be an important route of exposure
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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or various PAHs and percutaneous absorption of PAHs has been
hown before [9–11]. Moreover, a strong correlation between der-
al  exposure to PAHs and the occurrence of skin cancer has been
eported in the past [12].
Carcinogenic PAHs require activation through biotransforma-
ion to form reactive intermediates and to target biological
acromolecules such as DNA [5]. Cytochrome P450-dependent
onooxygenases (CYPs), in particular CYP1A1, 1A2 and 1B1, are
rimarily involved in the metabolism of PAHs [13,14]. Enzy-
atic generation of sterically hindered bay or fjord region
iol-epoxides and subsequent DNA adduct generation is consid-
red the dominant mechanism in chemical carcinogenesis resulting
n mutational miscoding [15]. Many bay region PAHs such as
enzo[a]pyrene (BAP) are activated through CYP1A1 [16]. By
ontrast, CYP1B1 seems to play a more important role in the
etabolism of fjord region PAHs such as dibenzo[a,l]pyrene (DALP;
UPAC notation: dibenzo[def,p]chrysene) [17]. Besides activation
hrough CYP enzymes, two other activation pathways are impor-
ant in PAH metabolism: the formation of radical cations by one
lectron oxidation via peroxidases [18], and the formation of o-
uinones by dihydrodiol dehydrogenases [19]. It is assumed that
ll three pathways—to different extents—might contribute to PAH-
ediated carcinogenesis [20]. Most PAHs act as activators of the
ryl hydrocarbon receptor (AHR) [21]. AHR activation then leads to
ene expression of metabolizing enzymes such as CYPs, which—in
urn—contribute to the formation of activated PAH metabolites and
ubsequent DNA damage. Besides its role in the enzymatic bio-
ransformation of xenobiotics, the AHR may  also contribute more
irectly to alterations in cell signaling and proliferation [22]. The
omplexity of PAH toxicity is further illustrated by the fact that the
evel of DNA adduct formation does not necessarily correlate with
he extent of tumor formation in skin [23,24].
BAP was classified as human carcinogen by IARC [25]. By con-
rast, chrysene (CRY) has less carcinogenic activity in comparison to
AP. It also contains a bay region that can be converted into reactive
iol-epoxide moieties though [26], which then may  induce cancer
n mice [27,28]. DALP is one of the strongest carcinogenic PAHs con-
aining a fjord region [29]. The described toxicological mechanisms
riggered by different PAHs might lead to interactions and non-
dditive effects if such compounds occur in mixtures [30]. Hence
isk assessment strategies for exposures to PAH mixtures need to
e developed.
The three selected PAHs applied in our study are present in the
nvironment and may  therefore come into contact with human
kin. All three PAHs possess different chemical structures and
arcinogenic potencies,5 but all of them are metabolized by CYP
nzymes. We  used an immortal human keratinocyte cell line
HaCaT) as an in vitro model to study the effects that occur upon
xposure to these PAHs. HaCaT cells have been shown to be a suit-
ble metabolically competent model system to mimic  human skin
ells [31]. We  examined the effects of the three selected PAHs
sing a targeted metabolomics approach by analyzing 188 endoge-
ous metabolites. Thereby we analyzed the end-products of cellular
etabolism via comparative analysis of endogenous metabolites
nd examined AHR-dependent changes induced in HaCaT cells. The
verall aim of our studies is to gain more molecular information on
he adverse signaling pathways associated with dermal exposures
o PAHs.
. Materials and methods.1. Chemicals
Cell culture media and supplements were purchased from PAN
iotech (Aidenbach, Germany). All other chemicals were purchasedports 3 (2016) 763–773
from Sigma Aldrich with the highest purity available (Munich,
Germany). Substances were routinely dissolved as stock solutions
in dimethylsulfoxide (DMSO).
2.2. Cell lines
Human adult wild-type (HaCaT WT)  and AHR knockdown
(HaCaT AHR-KD) keratinocyte cell lines were kindly provided by
Prof. Ellen Fritsche (IUF – Leibniz Research Institute for Environ-
mental Medicine, Germany) and are described elsewhere [32]. Both
cell lines were maintained in DMEM (Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal calf serum (FCS, v/v), 2 mM
l-glutamine, penicillin (100 U/mL), streptomycin (0.1 mg/mL) at
37 ◦C in humidified atmosphere with 5% CO2. After 24 h of initial
incubation the cells were exposed to the test substances.
2.3. MTT  assay
In brief, cells (2 × 105 cells/mL) were seeded in 24-well plates
and exposed to various concentrations (0–20 M)  of the chemicals
(BAP, CRY, DALP). The final concentration of DMSO did not exceed
0.1% (v/v). After 24 h and 48 h of exposure, MTT  reagent (0.5 mg/mL)
was added and incubated for 2 h at 37 ◦C, 5% CO2. Afterwards, for-
mazan crystals were dissolved by adding 400 L DMSO into each
well. The absorption of the samples was measured in triplicates on
a microplate TECAN reader at 595 nm.
2.4. Real-time PCR
For gene expression studies cells (2 × 105 cells/mL) were seeded
in 12-well plates and incubated in DMEM.  Cells were exposed to the
test substances for 24 h or 48 h, respectively. Following substance
treatment the total RNA was extracted using Trizol (Invitrogen,
Carlsbad, CA, USA). RNA quantity and quality was  determined using
a Nanodrop-1000 (Thermo Fisher Scientific, Asheville, NC, USA).
Subsequently, cDNA was  synthesized of 1 g of RNA using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA, USA). Levels of individual transcripts were then quan-
tified using SYBR®Green Fast (Applied Biosystems). Quantitative
real time-polymerase chain reaction (qRT-PCR) was performed
according to the manufacturer’s instructions on an ABI-7500
Fast Real Time PCR system (Applied Biosystems). Gene selective
primers for CYP1A1 (forward 5′-CCAAGAGTCCACCCTTCCCAGCT-
3′, reverse 5′-GAGGCCAGAAGAAACTCCG-TGGC-3′),
CYP1B1 (forward 5′-TGGATTTGGAGAACGTACCG-3′,
reverse 5′-CCACG-ACCTGATCCAATTCT-3′) and HPRT
(forward 5′-GTTCTGTGGCCATCTGCTTAG-3′, reverse 5′-
GCCCAAAGGGAACTGATAGTC-3′) were used. Relative gene
expression was calculated using the Ct method and nor-
malized to expression levels of HPRT. Vehicle control (0.1% DMSO)
sample expressions were set to a fold change value of 1 and used
as comparison for treated cells.
2.5. Western blots
Equal amounts of proteins (30 g) obtained from RIPA
buffer lysed cells were applied to SDS-PAGE, transferred onto
nitrocellulose membranes and immune-blotted according to the
manufacturer’s instructions. Antibodies against CYP1A1 (sc-20772)
and CYP1B1 (sc-32882) were used (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Primary antibody probed blots were visualized with
appropriate horseradish peroxidase-coupled secondary antibodies
(Santa Cruz Biotechnology) using enhanced chemo-luminescence
(34078; Thermo Scientific, Waltham, MA,  USA) for detection.
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.6. Cell culture for metabolomics approach
Cells (1 × 105 cells/mL) were seeded in 10 cm cell culture dishes
nd incubated in DMEM.  Cells were exposed to the test substances
4 replicates for each treatment) for 48 h. After substance treat-
ent, cells were quickly washed twice with ice-cold ammonium
ormate buffer solution (155 mM,  pH 7.4). Cells were detached from
he culture dish by scraping into 1 mL  of buffer solution, transferred
o 1.5 mL  safe-lock tubes (Eppendorf, Hamburg, Germany) and
entrifuged (500 × g, 5 min, 4 ◦C). After centrifugation the super-
atant was removed and the cell pellet weight was recorded before
reezing them in liquid nitrogen. The frozen samples were stored
ntil analysis at −80 ◦C A volume of 0.5 mL  UHPLC grade ice-cold
ethanol (J.T. Baker, Deventer, Holland) was added for cell pellet
xtraction followed by 3 freeze and thaw cycles: cells were frozen
or 5 min  in liquid nitrogen and afterwards thawed for 5 min  at
oom temperature followed by 1 min  of ultrasonication in a water
ath. After centrifugation (12,000 x g, 30 min, 4 ◦C), supernatants
ere immediately analyzed using the Biocrates AbsoluteIDQ p180
it.
.7. Targeted metabolomics approach
The AbsoluteIDQ platform (Kit p180, Biocrates, Innsbruck,
ustria) was employed for targeted metabolite profiling as
escribed by the manufacturer. This platform detects a total of 188
etabolites, including 42 amino acids (AAs) and biogenic amines
BAs), 40 acylcarnitines (Cx:y), hydroxyacylcarnitines (Cx:y-OH)
nd dicarboxyacylcarnitines (Cx:y-DC) (ACs), the sum of hex-
ses, 15 sphingomyelins (SM Cx:y) and sphingomyelin derivatives
SM(OH)Cx:y], as well as 14 lysophosphatidylcholines (LPC Cx:y)
nd 76 phosphatidylcholines (PC Cx:y). LPCs and PCs were fur-
her differentiated with respect to the presence of ester (“a”) or
ther (“e”) bonds in the glycerol moiety (“a” = acyl, “aa” = diacyl,
nd “ae” = acyl-alkyl). The lipid side chain composition is abbre-
iated with “Cx:y”; “x” denotes the number of carbons in the side
hain and “y” the number of double bonds. Detailed information
n the metabolites analyzed along with the protocol of metabo-
ite quantification is presented elsewhere [33]. The cellular extracts
ere prepared following the manufacturer’s protocol. Briefly, sam-
les were prepared as follows: (a) pipetting of a standard mixture
abeled with stable isotopes onto the filter paper inserts of the 96-
ell plate of the kit and drying under a stream of nitrogen using
n EVA LS evaporator (VLM, Bielefeld, Germany), (b) adding of 20
L cell extract onto the filter inserts and drying under a stream of
itrogen, (c) derivatization of AAs using phenylisothiocyanate, (d)
xtraction of metabolites and internal standards with 5 mM ammo-
ium acetate in methanol, (e) centrifugation through a membrane
lter followed by dilution with solvent for mass spectrometry. One
art of the eluate was diluted with 40% methanol in water (1/10
v/v)) for LC–MS/MS analysis, the other part with Biocrates kit run-
ing solvent (1/50 (v/v)) for FIA-MS/MS. The final extracts were
hen analyzed using a QTRAP 5500 (AB Sciex, Darmstadt, Germany)
riple quadrupole mass spectrometer coupled to an Agilent 1200
eries HPLC (Agilent, Waldbronn, Germany) using ESI MS/MS. For
he mass spectrometry analysis the software package Analyst 1.6
as used (AB Sciex, Darmstadt, Germany). LC–MS/MS analysis was
erformed in the positive mode which enables the quantification of
2 metabolites, covering 21 AAs and 21 BAs. A Zorbax Eclipse XDB-
18 column (3 × 100 mm,  3.5 m;  Agilent, Waldbronn, Germany)
as used for metabolite separation by LC. Subsequently, the FIA-
S/MS  procedure was used for the quantification of 146 additional
etabolites, covering 40 ACs including free carnitine, 38 PCaa’s,
8 PCae’s, 14 LPCs), 15 SMs, and the sum of hexoses in both pos-
tive and negative ion mode. Multiple reaction monitoring (MRM)
as used for quantification and compound identification using theports 3 (2016) 763–773 765
MetIDQTM software package which is an integral part of the Abso-
luteIDQ kit. Concentrations of all metabolites were calculated in
micromolar units. The method is in concordance with FDA guide-
lines, warranting reproducibility within a given error range [34].
Metabolite concentrations were standardized to cell pellet weight.
For statistical analyses, only metabolites were chosen which were
present in each sample, thus restricting the profile to a total of 166
metabolites.
2.8. Statistical analysis
Processing of metabolomics data was  carried out using the sta-
tistical package SPSS + (version 12.0.2G) as described elsewhere
[35]. In brief, each sample was standardized to the mean of the
control (set to 100%) and normalized using z-score values. Then, a
MANOVA (multivariate analysis of variance) including Bonferroni
correction was  used for compound selection and reduction of the
dataset to metabolites that are significantly changed in at least one
exposure group compared to controls. Metabolites that showed a
significant group difference (p ≤ 0.05) were selected for multivari-
ate analysis. Principal component analysis (PCA) was  performed
to achieve dimension reduction of the datasets and the resulting
factors were used for a post-hoc Fisher’s Discriminant analysis as
described elsewhere [36] for group separation. The performance of
the discriminant models was  subsequently verified by applying the
“leave-one-out” cross-validation formalism [37].
3. Results
Prior to the metabolomics analysis, dose-dependent cytotoxic-
ity was  investigated in HaCaT WT  and AHR-KD cells upon exposure
to each of the three PAHs (Fig. 1).
To indirectly assess AHR activation by these compounds, induc-
tion of the downstream genes CYP1A1 and CYP1B1 was examined
at different concentrations and at both the mRNA (Fig. 2) and the
protein level (Fig. 3).
After selection of appropriate concentrations and time-points
corresponding cellular metabolites were analyzed using a targeted
metabolomics platform.
3.1. Cytotoxicity
Cell viability was  only weakly affected in both cell lines after
treatment with up to 20 M BAP for 48 h (Fig. 1A). In HaCaT WT  cells
viability only decreased to about 80% at the highest concentration
applied. In contrast, CRY caused strong cytotoxic effects in both
cell lines (calculated EC50 values of 3.8 M for WT  and 2.0 M for
AHR-KD cells; Fig. 1B). Treatment with DALP also led to enhanced
cytotoxicity in WT  cells with a calculated EC50 value of 0.035 M
(Fig. 1C). On the other side, the viability of AHR-KD cells remained
unaffected at DALP concentrations of up to 20 M.
3.2. CYP induction on mRNA level
To investigate the activation of AHR by BAP, CRY or DALP, induc-
tion of the downstream genes CYP1A1 and CYP1B1 was measured at
the mRNA level. Both CYP enzymes are involved in the metabolism
of the three PAHs [13]. As expected, BAP caused a very strong and
concentration-dependent induction of CYP1A1 in WT but only a
slight elevation of transcription levels in AHR-KD cells after 24 h of
incubation (Fig. 2A). For CYP1B1 induction a clear chemical-related
effect could be observed as well albeit to a much lower extent.
Compared to BAP, CRY was  also found inducing both genes in WT
cells but less strongly. There was  again no significant induction
in AHR-KD cells (Fig. 2B). Conversely, DALP only weakly increased
766 S. Potratz et al. / Toxicology Re
Fig. 1. Toxicity of BAP, CRY and DALP in HaCaT wild-type (WT) or AHR knockdown
(AHR-KD) cells. Viability was  determined via MTT assay. Cells were treated with 7
different concentrations (0.1–20 M)  of BAP (A) and CRY (B) for 48 h. For DALP (C) 8
additional concentrations (0.01–0.08 M)  were tested due to the strong cytotoxicity
of this compound emerging in WT  cells. Controls contained 0.1% DMSO (vehicle).
Each experiment was repeated three times and data were expressed as mean ± SD.
The x-axis depicts the concentrations of the respective PAH applied, the y-axis shows
the viability of the treated cells in percent compared to the controls (set to 100%).
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patterns altered by the three PAHs that were essential for group
separation. All PAHs show a down-regulation of Gln. Furthermore,
metabolomics patterns of BAP and DALP show similarities in ahe transcription level of CYP1A1 and those of CYP1B1 were even
ess affected (Fig. 2C). Although this finding is matched by another
tudy where DALP showed similar results in the skin of mice [24],
t nevertheless seems kind of surprising and also pointed to the
ossibility that the time-points picked might have been too late to
ssess this end-point adequately. Therefore, we also tested earlier
ime-points (2 and 8 h) and confirmed that no significant induction
f CYP1A1 or CYP1B1 occurred upon treatment of HaCaT cells with
ALP concentrations of up to 1 M (data not shown).ports 3 (2016) 763–773
3.3. CYP induction on protein level
Western blots confirmed the qPCR data on the protein level. Both
CYP1A1 and CYP1B1 showed a strong concentration-dependent
induction by BAP, a moderate induction by CRY and no induction
by DALP in HaCaT WT  cells (Fig. 3). For AHR-KD cells faint signals
were detected for BAP only.
Based on the results obtained in cytotoxicity tests, qPCR and
western blots, concentrations of 1 M (BAP and CRY) and 0.01 M
(DALP) were selected to be applied in the subsequent metabolomics
study. HaCaT cells (WT  and AHR-KD) were exposed to each chemi-
cal for 48 h. This experimental setting uses a sub-toxic dose for each
PAH sufficient to activate the AHR in HaCaT WT  cells. Exposure for
48 h was regarded to be suitable for the detection of metabolomic
alterations. So, this time-point represents a scenario after maximal
AHR activation and CYP mRNA induction at which downstream CYP
protein levels were still found elevated.
3.4. Metabolomics approach: identification of metabolomics
biomarkers
In total, 166 metabolites were detected at all exposure sce-
narios and analyzed using the AbsoluteIDQ platform. For HaCaT
WT and AHR-KD cells 126 and 45 metabolites, respectively, were
selected for a multivariate model since they showed significant
group differences (p ≤ 0.05). PCA was  performed to achieve dimen-
sion reduction of the datasets and the resulting factors were used
for a post-hoc Fisher’s discriminant analysis resulting in group
separation as described elsewhere [36]. For HaCaT WT  cells, this
discriminant model resulted in 6 factors accounting for 100% of
the observed variance in the system. Evaluation of the PCA factors
that contributed most to discriminant functions F(×1) and F(×2)
revealed a high contribution (90% explanation of the overall vari-
ance observed) of PCA factors 1–3 to the separation. Interestingly,
mainly PCae’s and PCaa’s were loading high on factor 1, acylcar-
nitines on factor 2 and a mix  of metabolite classes including the
amino acid glutamine (Gln) and -aminoadipic acid (alpha-AAA)
were loading high on factor 3. For further data reduction the fol-
lowing thresholds were applied to the loading factors: for factor
1 ≥ 0.970, for factor 2 ≥ 0.950 and for factor 3 ≥ 0.330, respectively.
This methodology revealed 24 metabolites (see Table 1) that could
be used to achieve complete separation of all exposure groups and
controls in the model applied (Fig. 4).
The performance of the discriminant models was subsequently
verified by applying the “leave-one-out” cross-validation formal-
ism [37,38] resulting in 100% accuracy. In the case of HaCaT AHR-KD
cells, Fisher’s discriminant analysis of the selected 45 metabo-
lites led to a separation of the exposure groups by including
7 factors, but cross-validation revealed only 81.3% of accuracy.
One case of each exposure group was  falsely assigned: one BAP-
exposed sample was predicted as control, one CRY-treated sample
as DALP-treated sample and one DALP-treated sample as CRY-
treated sample. Accordingly, no reliable separation of exposure
groups in HaCaT AHR-KD cells could be achieved. In HaCaT WT cells,
the 24 identified metabolites that were used in the multivariate
model to distinguish between different treatment groups comprise
6 different metabolite classes (BAs, AAs, ACs, PCaa’s, PCae’s and
SMs, see Tbl. 1): the two polar metabolites alpha-AAA (BAs) and the
amino acid Gln, two  PCaa’s of medium chain length (i.e., PCaa C32:2
and PCaa C36:2), several PCae’s of medium and long chain length
as well as SM C16:1. Scatter dot plots (Fig. 4) show examples of
metabolites of each class providing insight in the metabolomicsstrong down-regulation of alpha-AAA and a strong up-regulation of
S. Potratz et al. / Toxicology Reports 3 (2016) 763–773 767
Fig. 2. Effect of BAP, CRY and DALP on the AHR target genes CYP1A1 and CYP1B1 in HaCaT WT and AHR-KD cells. Cells were exposed for 24 h and 48 h to (A) BAP (0.1 M,
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.0  M,  3.5 M),  (B) CRY (0.1 M,  1.0 M,  3.5 M),  and (C) DALP (0.01 M,  0.02 
xpression of CYP1A1 and CYP1B1 was subsequently quantified with SYBR Green u
n  endogenous gene (HPRT). The data represent the mean of two  independent expe
arnitines (e.g. C18:2). In contrast, PCaa’s, PCae’s and the SM C16:1
re lowered in DALP-treated cells and increased in those treated
ith BAP. For CRY-treated cells a slight elevation of 23 metabolites
as observed; here only Gln levels were down-regulated.
.5. Metabolomics approach: alterations of metabolomics profiles
y each PAH
We  used the described multivariate model to examine which
etabolites contribute to the separation of the three PAHs. In an
dditional statistical analysis we evaluated alterations, as caused by
ach PAH in comparison to non-treated controls, of the complete
etabolomics pattern consisting of a total of 166 metabolites. In
enn diagrams and volcano plots the metabolomics changes are
isualized (Fig. 5).3 M),  respectively. Controls contained 0.1% DMSO (vehicle) only. Relative gene
eal-time PCR. Target gene expression was normalized to the transcription level of
ts (±SD).
The plots depict the effects on the measured metabolites caused
by each PAH in HaCaT WT  cells. Venn diagrams (Fig. 5A) sum-
marizing all significant changes show the differential alterations
caused by the three compounds. Most of the changes were noticed
as up-regulations of the levels of metabolites mainly caused by
the two  potent carcinogens BAP and DALP. These two compounds
share a third of all up-regulated metabolites. Still 26 metabolites
are uniquely elevated upon BAP exposure. BAP is also sharing cer-
tain up-regulated metabolites with CRY, while DALP and CRY do
not have any metabolite changes in common. Down-regulation of
metabolites was  mainly caused by DALP with 30 uniquely altered
metabolites compared to none by BAP and CRY. Only Gln has
been consistently found down-regulated in all treatment groups
(BAP p = 0.001, CRY p = 0.008, DALP p = 0.002). Therefore we ver-
ified relative Gln levels by an enzymatic assay. As seen in the
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Fig. 3. Effect of BAP, CRY and DALP on the CYP1A1 (A) and CYP1B1 (B) protein levels of the in HaCaT WT and AHR-KD cells. Cells were treated for 24 h and 48 h with BAP
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0.1  M,  1 M,  3.5 M),  CRY (0.1 M,  1 M,  3.5 M),  and DALP (0.01 M,  0.02 M
MSO  (vehicle). Western-blot analysis of total protein lysates was  performed as de
argeted metabolomics approach, Gln was downregulated approx-
mately two-fold in HaCaT WT cells treated with BAP and DALP
Supplementary Fig. 4). However, this orthogonal method could
ot confirm the effect of CRY on Gln levels. In AHR-KD cells,
nly BAP provoked a decrease of Gln concentration in accordance
ith the LC–MS/MS measurements. Metabolomics profile changes
aused by BAP (Fig. 5B) and DALP (Fig. 5D) show similarities in
p-regulation of ACs (e.g., C18:2 BAP p = 0.01; DALP p ≤ 0.003),
Ms  (e.g., SM C26:0; BAP p = 0.025; DALP p = 0.009) and LPCs
e.g., LPC C14:0; BAP p = 0.008; DALP p = 0.007), as well as down-
egulation of AAs (e.g., Lys; BAP p = 0.034; DALP p ≤ 0.0005) and one
A (i.e., alpha-AAA; BAP p = 0.004; DALP p ≤ 0.0005) (Supplemen- M), respectively. Controls remained either untreated or were treated with 0.1%
d in the Section 2. Data shown are representative for two biological replicates.
tary Tbl. 1). Treatment with BAP specifically induces a significant
up-regulation of 9 SMs  and SM(OH)s, for example SM(OH) C14:1
(p = 0.006) and SM C24:0 (p = 0.009), which are not altered in DALP-
or CRY-treated cells (Supplementary Tbl. 1). In the case of DALP 37
ACs are significantly up-regulated. Twenty eight among them are
also found up-regulated in cells treated with BAP. Conversely, treat-
ment of WT cells with CRY did not affect its AC levels. The treatment
of cells with DALP is further down-regulating 11 PCae’s that remain
unaffected upon exposure to BAP and CRY. Twenty PCaa’s were
found increased in cells after BAP exposure, 12 of which are also up-
regulated after CRY exposure. Treatment with DALP caused a strong
down-regulation of 15 AAs and 3 BAs (i.e., alpha-AAA, sarcosine,
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Fig. 4. Fisher’s discriminant analysis of targeted metabolomics data obtained in HaCaT WT cells. Cells were treated with BAP (1 M),  CRY (1 M)  or DALP (0.01 M) for
48  h in 4 replicates. Control samples contain 0.1% DMSO only. Metabolites of total cell extracts were analyzed using the p180 Kit from BIOCRATES. In HaCaT WT  cells 24
metabolites contributed to a group separation between the three different PAH exposure groups and the control. Cross-validation of the data revealed a re-grouping of 100%
using  the leave-one-out system. Scatter dot plots for each exposure group (BAP, CRY and DALP) show the metabolic patterns of selected metabolites picked from the group
of  24 metabolites that contributed to group separation. The short black lines refer to the mean values ± SD. The long red lines refer to the relative mean values of untreated
controls which were set to 100%.
Table 1
List of 24 metabolites revealing with significant changes between the different treatment groups of HaCaT WT  cells (p-values result from MANOVA; metabolite
concentrations in nmol/g pellet weight ± SD). Abbreviations used: BAs = biogenic amines (alpha-AAA = a-aminoadipic acid); ACs = acylcarnitines (Cx:y = acylcarnitines, Cx:y-
OH  = hydroxyacylcarnitines, Cx:y-DC = dicarboxyacylcarnitines); AAs = amino acids (Gln = glutamine); PCs = phosphatidylcholines (PCaa Cx:y = diacyl, PCae Cx:y = acyl-alkyl);
SMs  = sphingomyelines (SM Cx:y); x = number of carbon atoms in the lipid chain, y = number of double bonds.
Metabolite Category Control BAP CRY DALP P value
alpha-AAA BAs 11.2 ± 0.9 5.7 ± 1.8 14.2 ± 3.8 2.0 ± 1.1 0.000
C10:2 ACs 0.7 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 0.001
C12:1 0.9 ± 0.1 1.2 ± 0.1 1.0 ± 0.2 1.4 ± 0.1 0.000
C12-DC 2.9 ± 0.3 3.8 ± 0.2 3.3 ± 0.6 4.2 ± 0.2 0.001
C18:1-OH 0.7 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 1.0 ± 0.0 0.001
C6  (C4:1-DC) 1.7 ± 0.3 2.3 ± 0.2 1.9 ± 0.3 2.5 ± 0.2 0.004
C18:2 0.7 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 1.1 ± 0.1 0.000
C4  2.0 ± 0.3 2.5 ± 0.3 2.3 ± 0.5 2.9 ± 0.3 0.029
C4:1  0.8 ± 0.1 1.1 ± 0.1 0.9 ± 0.2 1.3 ± 0.1 0.001
Gln  AAs 149.4 ± 12.4 77.1 ± 18.2 114.3 ± 12.8 65.7 ± 23.9 0.000
PCaa  C32:2 PCs (aa) 109.8 ± 12.4 103.6 ± 11.5 127.8 ± 17.3 81.9 ± 9.5 0.003
PCaa  C36:2 1644.0 ± 221.7 2039.2 ± 198.8 2097.1 ± 262.1 1417.7 ± 173.7 0.002
PCae  C32:1 PCs (ae) 196.3 ± 29.9 198.8 ± 17.1 231.2 ± 36.0 164.7 ± 17.4 0.029
PCae  C34:2 224.4 ± 36.1 238.2 ± 23.8 275.4 ± 48.2 170.7 ± 25.4 0.009
PCae  C34:3 24.4 ± 3.0 26.8 ± 3.1 29.7 ± 5.0 20.8 ± 3.3 0.031
PCae  C36:2 309.1 ± 43.7 354.1 ± 28.2 385.0 ± 53.6 235.3 ± 25.3 0.001
PCae  C36:3 96.2 ± 15.0 108.6 ± 10.5 120.5 ± 17.9 65.2 ± 8.9 0.001
PCae  C38:1 23.7 ± 4.2 29.7 ± 2.2 29.9 ± 5.0 18.7 ± 1.2 0.002
PCae  C38:2 62.5 ± 9.7 74.9 ± 6.3 78.0 ± 13.3 50.7 ± 5.2 0.004
PCae  C38:3 27.3 ± 3.6 33.8 ± 3.9 34.7 ± 5.8 18.5 ± 1.8 0.000
PCae  C38:4 58.2 ± 7.5 69.0 ± 7.3 70.5 ± 9.1 38.1 ± 4.0 0.000
PCae  C40:4 10.1 ± 1.5 11.7 ± 1.5 12.8 ± 2.0 7.6 ± 0.5 0.002
PCae  C40:5 26.3 ± 4.4 30.0 ± 2.5 33.3 ± 4.2 16.5 ± 1.5 0.000
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SM  C16:1 SMs  29.5 ± 2.8 35.3
aurine). By contrast, treatment of cells with CRY and BAP resulted
n the down-regulation of only 1 (Gln) and 3 (Ala, Gln and Lys) AAs,
espectively. In CRY-exposed cells, many PCaa’s and PCae’s were
p-regulated similarly to BAP-exposed cells. On the other side, SM,
C, LPC and BA concentrations remained completely unaffected in
aCaT WT cells upon treatment with CRY when compared to con-
rol cells. The results obtained for AHR-KD cells are presented in
upplementary Fig. 1 and Supplementary Tbl. 2.35.0 ± 3.8 25.5 ± 2.1 0.002
4. Discussion
Carcinogenic PAHs occur in crude oil fractions used for the
production of rubber, certain plastics and elastomers. Since ker-
atinocytes are potential target cells for PAH exposure we  studied
the influence of BAP, CRY and DALP on 166 endogenous metabo-
litesof HaCaT cells. HaCaT cells represent a non-tumorigenic
permanent epithelial cell line from adult human skin [39] which
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Fig. 5. Differential alterations of metabolomics profiles caused by BAP, CRY and DALP in HaCaT WT cells. Venn diagrams of up- and down-regulated levels of metabolites
(A).  Volcano plots of metabolites influenced by each single PAH compared to control; BAP (B), CRY (C) and DALP (D). Fold changes were calculated as the ratio between the
median of the two groups compared. The significance expressed as p-values is calculated by a two-sided, unpaired t-test. (B–D) The x-axes represent the fold changes as log2
values  of the ratio between the median of the treated cells compared to untreated controls. The y-axes represent the −log10 values of the determined p-values via t-test.
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xes  on the right side represent the p-values (p < 0.05 is regarded as significant). O
cylcarnitines; BAs, biogenic amines; PCs, phosphatidylcholines; LPCs, lysophospha
s known to be metabolically competent [40]. Hence, exposure of
hese cells against PAHs may  lead to PAH biotransformation and
he activation of certain toxicological signaling cascades involved
n the expression of an adverse outcome.
.1. PAH-mediated cytotoxicity and influence on CYP1A1 and
YP1B1 expression
Even though BAP is metabolized in HaCaT WT  cells to its ultimate
arcinogen (—)-anti-BAP-7,8-diol-9,10-epoxide (BPDE) [40] and
as been shown to cause metabolism-independent pro-apoptotic
ffects [41], viability tests revealed only little cytotoxicity of BAP
n HaCaT WT  or AHR-KD cells after 48 h at the concentrations
pplied. Compared to the other two PAHs investigated, BAP caused
 strong induction of CYP1A1 and CYP1B1 on both mRNA and
rotein level (Figs. 1 and 2). This is in accordance with its high
otency to bind and activate the AHR [42]. However, besides CYP top axis, fold changes are presented. Abbreviations used: AAs, amino acids; ACs,
holines; SMs, sphingomyelins.
induction, AHR activation may also promote defensive mecha-
nisms such as, e.g., the synthesis of glutathione S-transferases
(GST) [5], which then—in turn—may detoxify BAP-derived elec-
trophiles such as BPDE [43]. This mechanism might contribute
to the high tolerance of HaCaT cells against BAP. On the other
side, the tetracyclic PAH CRY revealed with some cytotoxicity in
HaCaT cells irrespective of its AHR expression status and most
likely due to the induction of oxidative stress [44]. Conversely,
DALP showed very strong cytotoxicity only in HaCaT WT  cells (EC50:
approx. 0.035 M)  without inducing CYP1A1 or CYP1B1. Since the
strong cytotoxicity of DALP was observed in HaCaT WT without
significant induction of CYP enzymes, but completely disappeared
in HaCaT AHR-KD cells, AHR-dependent toxicity of DALP in this
particular cell line seems rather mediated through other mecha-
nisms than diol-epoxide-DNA adduct formation. Notwithstanding,
formation of DALP-11,12-diol-13,14-epoxides (DALPDE) has been
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lready shown to contribute to DALP-mediated cytotoxicity in cer-
ain cell models such as mouse embryo fibroblasts [45].
.2. Effects of BAP, CRY and DALP on metabolites of HaCaT WT
nd AHR-KD cells
For the first time a metabolomics analysis was conducted in
aCaT cells and the differential influences of the three selected
AHs were recorded and considered as individual signatures of
oxicity. Applying a multivariate model, the 166 metabolites ana-
yzed allowed no separation of the different exposure groups
n HaCaT AHR-KD cells while HaCaT WT  cells revealed strongly
ltered and differentiable metabolomics profiles (Figs. 4 and 5).
his result points to differences of AHR signaling dependent on
he particular PAH used. Since CYP1A1 and CYP1B1 expression
as found significantly increased in WT  cells treated with BAP and
RY (Figs. 2 and 3), metabolites formed through enzyme-mediated
atalysis most likely contributed to the overall metabolomics
lterations observed with these two PAHs. On the other hand,
ALP-treated WT  cells showed a lack of considerable CYP induc-
ion. In addition, metabolite levels remained virtually unaffected
n AHR knockdown cells treated with DALP (Supplementary Fig.
). Aiming to explain these results for DALP, we considered three
ossible reasons: Firstly, AHR-KD cells might become insensitive
gainst PAH effects and differentiate differently due to the lack
f AHR. Contrasting this assumption, however, on the metabolite
evels only minor changes between AHR-KD cells and WT cells
ould be detected in untreated controls (Supplementary Fig. 2).
econdly, albeit extremely low, basal CYP1B1 levels in WT  cells
ould be sufficient for the formation of genotoxic metabolites of
ALP. We  detected 4-fold lower basal CYP mRNA levels in AHR-KD
ells compared to WT  cells (Supplementary Fig. 3). Also Topinka
t al. found a negligible CYP induction at DALP concentrations that
evertheless caused high levels of DNA adducts [46]. A 10,000 fold
eduction of basal CYP1B1 levels has been shown after knockout of
HR in MCF-7 cells [47]. As CYP1B1 is mainly responsible for DALP’s
etabolic activation [48], a decrease in the cellular level of this
nzyme might explain the insensitivity of AHR-KD cells against the
otential toxicity of this compound. Thirdly, the AHR-dependent
oxicity of DALP could also be caused by non-genotoxic AHR sig-
aling alone. Although not investigated yet DALP might function
s a selective AHR modulator (SAHRM), thereby triggering alter-
ative AHR responses without xenobiotic response element (XRE)
ctivation [49].
.3. Alterations in metabolite levels of amino acids and biogenic
mines
The levels of the amino acid Gln were found strongly lowered
pon exposure of HaCaT WT  cells to BAP and DALP and weakly
pon CRY exposure (Figs. 4 and 5). Conversely, in AHR-KD cells Gln
evels were only decreased compared to controls upon treatment
ith BAP, but not in cells treated with CRY or DALP (Supplementary
igs. 1, 4). Significantly depleted levels of Gln have been reported in
he literature in lung-derived A549 cells treated with different PAH
uinones [50]. Since BAP quinones can easily be generated via both
YP-mediated monooxygenation followed by non-enzymatic oxi-
ation and peroxidase-mediated one-electron oxidation [5], in the
bsence of a functional AHR the contribution of the latter pathway
ight become more relevant in the generation of PAH quinones.
The strong depletion in the levels of Gln points to a PAH-
ediated impairment of both glycolysis and the tricarboxyclic acid
TCA) cycle whose intermediates provide anabolic precursors for
he biosynthesis of fatty acids, nucleic acids, and proteins. This
s further supported by significantly reduced levels of alpha-AAA,
n intermediate in lysine biosynthesis, which has also been foundports 3 (2016) 763–773 771
depleted in HaCaT cells after exposure to BAP or DALP (Fig. 5, Sup-
plementary Tbl. 1). Altogether, the levels of 15 AAs were decreased
after DALP exposure (Supplementary Tbl. 1). Three of them (Ala,
Gln and Lys) were also lowered in HaCaT cells after exposure to
BAP. In particular, Glu and Gly are necessary in the biosynthesis
of glutathione (GSH), a tripeptide which acts as protective agent
against reactive PAH metabolites such as DALPDE and thus can pre-
vent DNA adduct formation [43]. Therefore, depletion of these AAs
could be also due to enhanced GSH synthesis.
4.4. Alterations in the lipid metabolite profile caused by the three
different PAHs
Upon conversion of long-chain acyl-CoAs into ACs, these prod-
ucts are actively transported across the inner mitochondrial
membrane in exchange for free carnitine. Then, through catalysis
of carnitine acyltransferase II, acyl-CoA is being recovered within
the mitochondrial matrix and directed towards -oxidation [51].
Recently, Westmann et al. showed that fatty acid -oxidation in
chicken embryo liver was significantly reduced in response to the
treatment with a mixture of 16 different PAHs [52]. In transgenic
mice activation of AHR inhibited hepatic fatty acid -oxidation
along with acyl-CoA oxidase 1, the rate limiting enzyme in perox-
isomal -oxidation [53]. Down-regulation of acyl-CoA synthetase
was shown after BAP exposure of marine diatoms, thus provid-
ing evidence that PAHs may  interfere with the regulation of lipid
metabolism [54]. In our experiments significant increases of AC lev-
els have been detected in HaCaT WT  cells after exposure to BAP or
DALP (Fig. 5, Supplementary Tbl. 1). A more than 3-fold increase
of carnitine palmitoyltransferase 1 (CPT1), which is localized in
the outer mitochondrial membrane, and is responsible for the for-
mation of ACs by catalyzing the transfer of the acyl group of a
long-chain acyl-CoA to carnitine, was  reported in the liver of rats
upon treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
[55,56]. This might explain why  ACs start to accumulate in cells
that have been challenged by the carcinogens BAP and DALP. TCDD
is known as a strong AHR inducer, thus the detected changes may  be
linked to AHR activation. While the exact molecular mechanisms of
this interference between these carcinogenic PAHs and AC degrada-
tion remain obscure, lowered rates of ß-oxidation and subsequent
TCA cycle activity can explain why AA profiles were found strongly
decreased under the very same conditions (Fig. 5, Supplementary
Tbl. 1).
The phospholipid groups of PCs and SMs  are important compo-
nents of cell membranes and involved in regulation of cell function,
membrane protein trafficking and inflammation [57]. PAHs are
highly lipophilic compounds that can be directly incorporated into
the cell membrane thereby disturbing the biological membrane
function [58]. Perturbation of membrane’s integrity and the ulti-
mate loss of functionality have been shown in diatoms upon BAP
exposure [54] and might also be causative for the strong PC levels
changes observed in our study (Supplementary Tbl. 1). Addition-
ally, inducing canonical AHR signaling can be assumed to play a
role in the phospholipid pattern changes of HaCaT cells exposed
to BAP or CRY, but not to DALP. A recent study predicted genes
like PPAR and Lpin involved in lipid biosynthesis to be direct AHR
targets [59]. An activation of PPAR was  also found in a recent
proteomics study using Hepa1c1c7 cells exposed to BAP [60]. Yet,
this interference of AHR signaling with lipid metabolism is still
poorly understood. For instance, the PCaa C36:2 levels of cells were
only increased after BAP and CRY exposure and therefore identified
as a potential biomarker for canonical AHR activation after PAH
exposure. PCaa C36:2 was also detected as a possible biomarker to
distinguish smokers from non-smokers in the KORA (Cooperative
Health Research in the Region of Augsburg, Germany) study [61]. As
cigarette smoke contains a mixture of carcinogenic PAHs including
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AP [62], our data provide further evidence that this particular lipid
an serve as biomarker indicating the exposure of cells against AHR
ctivating PAHs. By contrast, DALP, that did not induce AHR down-
tream signaling in HaCaT cells (i.e., induction of CYP enzymes),
ndeed caused a measurable but insignificant decrease in the level
f PCaa C36:2 (Tbl. 1).
The increases of the levels of certain SMs  (i.e., SM(OH) C24:1,
M C18:0, SM C26:0, SM C26:1) found in HaCaT WT  cells after
reatment with BAP or DALP can be associated with the
nset of apoptosis. Sphingolipids represent a complex group of
iomolecules that function as transducers in eukaryotic cells, mod-
lating cell growth, differentiation and cell death [63]. SMs  can
e hydrolyzed by sphingomyelinase (SMase) to ceramides. After
ydrolysis of SMs, ceramides can function as second messengers
ctivating various cytokines such as TNF- that are involved in the
ignaling of apoptosis [64]. Therefore, the increases of SM levels
ound in cells after exposure to the strong carcinogens BAP and
ALP are likely a result of the pro-apoptotic effects of these com-
ounds. Exposure of HaCaT WT  cells against BAP at concentrations
nown to activate the AHR revealed a strong enhancement of CD95
Fas)-mediated apoptosis [41], which can similarly be triggered by
eramides [65].
. Conclusion
Applying a multivariate model we have identified altogether 24
iomarkers in HaCaT WT  cells that revealed sufficient to discrimi-
ate between exposure groups after treatment with three different
AHs. In previous PAH toxicity studies, long known cellular end-
oints such as CYP1A1 induction and DNA adduct formation have
een repeatedly proposed to be used in the risk assessment of
hese environmental pollutants. The data presented complement
his set of rather historical biomarkers by novel metabolites origi-
ating from lipid metabolism and turnover. The alterations in the
etabolomics profiles measured suggest influences of PAHs on the
nergy and lipid metabolism in the cells investigated.
This study is a proof of principle work using single compound
xposure only. As PAH exposure might lead to interactions if such
ompounds occur in mixtures, in future experiments binary mix-
ures as well as multi PAH mixtures should be studied and the
esulting metabolomic pattern changes compared. We  would sug-
est experiments using PAH concentrations with identical potency
n combination with experiments investigating co-exposure sce-
arios, where one of the investigated chemicals is at low dose in
rder to identify additive or synergistic effects. Further mechanis-
ic insights should be gained by experiments that relate metabolic
hanges to toxicological pathways. By specific inhibition of steps
n relevant signaling pathways (e.g., AHR, p53 or Nrf2) resulting
etabolomic marker sets could be related to those pathway steps.
his way metabolomic biomarkers indicative for inhibition or acti-
ation of relevant signaling pathways could be identified [35]. All
his information would finally help to develop in vitro risk assess-
ent strategies for PAH mixtures.
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